## House File 567

## H-8290

- 1 Amend the amendment, H-8289, to the Senate
- 2 amendment, H-1340, to House File 567, as amended,
- 3 passed, and reprinted by the House, as follows:
- 4 l. By striking page 1, line 1, through page 26,
- 5 line 30, and inserting:
- 6 <Amend the Senate amendment, H-3140, to House File
- 7 567, as amended, passed, and reprinted by the House,
- 8 as follows:
- 9 1. By striking page 1, line 1, through page 15,
- 10 line 26, and inserting:
- 11 <Amend House File 567, as amended, passed, and</pre>
- 12 reprinted by the House, as follows:
- 13 l. By striking everything after the enacting clause
- 14 and inserting:
- 15 < DIVISION I
- 16 MEDICAL CANNABIDIOL
- 17 Section 1. Section 124.401, subsection 5,
- 18 unnumbered paragraph 3, Code 2016, is amended to read
- 19 as follows:
- 20 A person may knowingly or intentionally recommend,
- 21 possess, use, dispense, deliver, transport, or
- 22 administer cannabidiol if the recommendation,
- 23 possession, use, dispensing, delivery, transporting,
- 24 or administering is in accordance with the provisions
- 25 of chapter 124D 124E. For purposes of this paragraph,
- 26 "cannabidiol" means the same as defined in section
- 27 <del>124D.2</del> 124E.2.
- 28 Sec. 2. NEW SECTION. 124E.1 Short title.
- 29 This chapter shall be known and may be cited as the
- 30 "Medical Cannabidiol Act".
- 31 Sec. 3. NEW SECTION. 124E.2 Definitions.
- 32 As used in this chapter:
- 33 1. "Debilitating medical condition" means any of the
- 34 following:
- 35 a. Cancer, if the underlying condition or treatment

- 1 produces one or more of the following:
- 2 (1) Severe or chronic pain.
- 3 (2) Nausea or severe vomiting.
- 4 (3) Cachexia or severe wasting.
- 5 b. Multiple sclerosis with severe and persistent
- 6 muscle spasms.
- 7 c. Seizures, including those characteristic of 8 epilepsy.
- 9 d. AIDS or HIV as defined in section 141A.1.
- 10 e. Crohn's disease.
- 11 f. Amyotrophic lateral sclerosis.
- 12 g. Any terminal illness, with a probable life
- 13 expectancy of under one year, if the illness or its
- 14 treatment produces one or more of the following:
- 15 (1) Severe or chronic pain.
- 16 (2) Nausea or severe vomiting.
- 17 (3) Cachexia or severe wasting.
- 18 2. "Department" means the department of public
- 19 health.
- 20 3. "Disqualifying felony offense" means a violation
- 21 under federal or state law of a felony under federal or
- 22 state law, which has as an element the possession, use,
- 23 or distribution of a controlled substance, as defined
- 24 in 21 U.S.C. §802(6).
- 25 4. "Health care practitioner" means an individual
- 26 licensed under chapter 148 to practice medicine and
- 27 surgery or osteopathic medicine and surgery.
- 28 5. "Medical cannabidiol" means a nonpsychoactive
- 29 cannabinoid found in the plant Cannabis sativa L.
- 30 or, Cannabis indica or any other preparation thereof
- 31 that is essentially free from plant material, and has
- 32 a tetrahydrocannabinol level of no more than three
- 33 percent, and that is delivered in any of the following
- 34 forms:
- 35 a. Liquid, including but not limited to oil.

- b. Pill. 1
- 2 Through a vaporized delivery method with the use
- 3 of liquid or oil but which does not include the use of
- 4 dried leaves or plant form.
- "Primary caregiver" means a person including but 5
- 6 not limited to a parent or legal guardian, at least
- 7 twenty-one years of age, who has been designated by
- 8 a patient's health care practitioner as a necessary
- 9 caretaker taking responsibility for managing the
- 10 well-being of the patient with respect to the use of
- 11 medical cannabidiol pursuant to the provisions of this
- 12 chapter.
- 7. "Written certification" means a document signed 13
- 14 by a health care practitioner, with whom the patient
- 15 has established a patient-provider relationship, which
- 16 states that the patient has a debilitating medical
- 17 condition and identifies that condition and provides
- 18 any other relevant information.
- 19 Sec. 4. NEW SECTION. 124E.3 Health care
- 20 practitioner certification duties.
- 21 Prior to a patient's submission of an
- 22 application for a medical cannabidiol card pursuant to
- 23 section 124E.4, a health care practitioner shall do all
- 24 of the following:
- 25 Determine, in the health care practitioner's
- 26 medical judgment, whether the patient whom the health
- 27 care practitioner has examined and treated suffers from
- 28 a debilitating medical condition that qualifies for
- 29 the use of medical cannabidiol under this chapter, and
- 30 if so determined, provide the patient with a written
- 31 certification of that diagnosis.
- 32 Provide explanatory information as provided by
- 33 the department to the patient about the therapeutic
- 34 use of medical cannabidiol and the possible risks,
- 35 benefits, and side effects of the proposed treatment.

rh/rj

- Subsequently, the health care practitioner shall
- 2 do the following:
- 3 a. Determine, on an annual basis, if the patient
- 4 continues to suffer from a debilitating medical
- 5 condition and, if so, issue the patient a new
- 6 certification of that diagnosis.
- 7 b. Otherwise comply with all requirements
- 8 established by the department pursuant to rule.
- 9 3. A health care practitioner may provide, but has
- 10 no duty to provide, a written certification pursuant
- ll to this section.
- 12 Sec. 5. NEW SECTION. 124E.4 Medical cannabidiol
- 13 registration card.
- 14 1. Issuance to patient. Subject to subsection 7,
- 15 the department may approve the issuance of a medical
- 16 cannabidiol registration card by the department of
- 17 transportation to a patient who:
- 18 a. Is at least eighteen years of age.
- 19 b. Is a permanent resident of this state.
- 20 c. Submits a written certification to the
- 21 department signed by the patient's health care
- 22 practitioner that the patient is suffering from a
- 23 debilitating medical condition.
- 24 d. Submits an application to the department, on a
- 25 form created by the department, in consultation with
- 26 the department of transportation, that contains all of
- 27 the following:
- 28 (1) The patient's full name, Iowa residence
- 29 address, date of birth, and telephone number.
- 30 (2) A copy of the patient's valid photograph
- 31 identification.
- 32 (3) Full name, address, and telephone number of the
- 33 patient's health care practitioner.
- 34 (4) Full name, residence address, date of birth,
- 35 and telephone number of each primary caregiver of the

- 1 patient, if any.
- 2 (5) Any other information required by rule.
- 3 e. Has not been convicted of a disqualifying felony 4 offense.
- 5 2. Patient card contents. A medical cannabidiol
- 6 registration card issued to a patient by the department
- 7 of transportation pursuant to subsection 1 shall
- 8 contain, at a minimum, all of the following:
- 9 a. The patient's full name, Iowa residence address,
- 10 and date of birth.
- 11 b. The patient's photograph.
- 12 c. The date of issuance and expiration date of the
- 13 registration card.
- 14 d. Any other information required by rule.
- 15 3. Issuance to primary caregiver. For a patient in
- 16 a primary caregiver's care, subject to subsection 7,
- 17 the department may approve the issuance of a medical
- 18 cannabidiol registration card by the department of
- 19 transportation to the primary caregiver who:
- 20 a. Is at least twenty-one years of age.
- 21 b. Submits a written certification to the
- 22 department signed by the patient's health care
- 23 practitioner that the patient in the primary
- 24 caregiver's care is suffering from a debilitating
- 25 medical condition.
- 26 c. Submits an application to the department, on a
- 27 form created by the department, in consultation with
- 28 the department of transportation, that contains all of
- 29 the following:
- 30 (1) The primary caregiver's full name, residence
- 31 address, date of birth, and telephone number.
- 32 (2) The patient's full name.
- 33 (3) A copy of the primary caregiver's valid

-5-

- 34 photograph identification.
- 35 (4) Full name, address, and telephone number of the

- 1 patient's health care practitioner.
- 2 (5) Any other information required by rule.
- 3 d. Has not been convicted of a disqualifying felony 4 offense.
- 5 4. Primary caregiver card contents. A medical
- 6 cannabidiol registration card issued by the department
- 7 of transportation to a primary caregiver pursuant to
- 8 subsection 3 shall contain, at a minimum, all of the
- 9 following:
- 10 a. The primary caregiver's full name, residence
- ll address, and date of birth.
- 12 b. The primary caregiver's photograph.
- c. The date of issuance and expiration date of the
- 14 registration card.
- 15 d. The registration card number of each patient
- 16 in the primary caregiver's care. If the patient
- 17 in the primary caregiver's care is under the age of
- 18 eighteen, the full name of the patient's parent or
- 19 legal guardian.
- 20 e. Any other information required by rule.
- 21 5. Expiration date of card. A medical cannabidiol
- 22 registration card issued pursuant to this section shall
- 23 expire one year after the date of issuance and may be
- 24 renewed.
- 25 6. Card issuance department of
- 26 transportation. The department may enter into
- 27 a chapter 28E agreement with the department of
- 28 transportation to facilitate the issuance of medical
- 29 cannabidiol registration cards pursuant to subsections
- 30 1 and 3.
- 31 7. Federally approved clinical trials. The
- 32 department shall not approve the issuance of a medical
- 33 cannabidiol card pursuant to this section for a patient
- 34 who is enrolled in a federally approved clinical trial
- 35 for the treatment of a debilitating medical condition

- 1 with medical cannabidiol.
- 2 Sec. 6. NEW SECTION. 124E.5 Department duties —
- 3 rules.
- 4 l. a. The department shall maintain a confidential
- 5 file of the names of each patient to or for whom the
- 6 department issues a medical cannabidiol registration
- 7 card and the name of each primary caregiver to whom the
- 8 department issues a medical cannabidiol registration
- 9 card under section 124E.4.
- 10 b. Individual names contained in the file shall be
- 11 confidential and shall not be subject to disclosure,
- 12 except as provided in subparagraph (1).
- 13 (1) Information in the confidential file maintained
- 14 pursuant to paragraph "a" may be released on an
- 15 individual basis to the following persons under the
- 16 following circumstances:
- 17 (a) To authorized employees or agents of the
- 18 department and the department of transportation as
- 19 necessary to perform the duties of the department and
- 20 the department of transportation pursuant to this
- 21 chapter.
- 22 (b) To authorized employees of law enforcement
- 23 agencies of a state or political subdivision thereof,
- 24 but only for the purpose of verifying that a person
- 25 is lawfully in possession of a medical cannabidiol
- 26 registration card issued pursuant to this chapter.
- 27 (c) To any other authorized persons recognized by
- 28 the department by rule, but only for the purpose of
- 29 verifying that a person is lawfully in possession of a
- 30 medical cannabidiol registration card issued pursuant
- 31 to this chapter.
- 32 (2) Release of information pursuant to subparagraph
- 33 (1) shall be consistent with the federal Health
- 34 Insurance Portability and Accountability Act of 1996,
- 35 Pub. L. No. 104-191.

- The department shall adopt rules pursuant to
- 2 chapter 17A to administer this chapter which shall
- 3 include but not be limited to rules to do all of the
- 4 following:
- 5 a. Govern the manner in which the department shall
- 6 consider applications for new and renewal medical
- 7 cannabidiol registration cards.
- 8 b. Ensure that the medical cannabidiol registration
- 9 card program operates on a self-sustaining basis.
- 10 c. Review and publicly report the existing medical
- 11 and scientific literature regarding the range of
- 12 recommended dosages for each debilitating medical
- 13 condition and the range of chemical compositions of
- 14 any plant of the genus cannabis that will likely be
- 15 medically beneficial for each of the debilitating
- 16 medical conditions. The department shall make this
- 17 information available to patients with debilitating
- 18 medical conditions beginning December 1, 2016, and
- 19 update the information annually.
- 20 Sec. 7. NEW SECTION. 124E.6 Use of medical
- 21 cannabidiol affirmative defenses.
- 22 l. A health care practitioner, including any
- 23 authorized agent or employee thereof, shall not be
- 24 subject to prosecution for the unlawful certification,
- 25 possession, or administration of marijuana under the
- 26 laws of this state for activities arising directly
- 27 out of or directly related to the certification or
- 28 use of medical cannabidiol or medical cannabidiol
- 29 products in the treatment of a patient diagnosed with
- 30 a debilitating medical condition as authorized by this
- 31 chapter.
- 32 2. a. In a prosecution for the unlawful possession
- 33 of marijuana under the laws of this state, including
- 34 but not limited to chapters 124 and 453B, it is an
- 35 affirmative and complete defense to the prosecution

- 1 that the patient has been diagnosed with a debilitating
- 2 medical condition, used or possessed medical
- 3 cannabidiol or medical cannabidiol products pursuant
- 4 to a certification by a health care practitioner as
- 5 authorized under this chapter, and, for a patient
- 6 eighteen years of age or older, is in possession of
- 7 a valid medical cannabidiol registration card issued
- 8 pursuant to this chapter.
- 9 b. In a prosecution for the unlawful possession
- 10 of marijuana under the laws of this state, including
- 11 but not limited to chapters 124 and 453B, it is an
- 12 affirmative and complete defense to the prosecution
- 13 that the person possessed medical cannabidiol or
- 14 medical cannabidiol products because the person is a
- 15 primary caregiver of a patient who has been diagnosed
- 16 with a debilitating medical condition and is in
- 17 possession of a valid medical cannabidiol registration
- 18 card issued pursuant to this chapter, and where
- 19 the primary caregiver's possession of the medical
- 20 cannabidiol or medical cannabidiol products is on
- 21 behalf of the patient and for the patient's use only as
- 22 authorized under this chapter.
- 23 c. If a patient or primary caregiver is charged
- 24 with the unlawful possession of marijuana under the
- 25 laws of this state, including but not limited to
- 26 chapters 124 and 453B, and is not in possession of
- 27 the person's medical cannabidiol registration card,
- 28 any charge or charges filed against the person shall
- 29 be dismissed by the court if the person produces to
- 30 the court prior to or at the person's trial a medical
- 31 cannabidiol registration card issued to that person and
- 32 valid at the time the person was charged.
- 33 3. An agency of this state or a political
- 34 subdivision thereof, including any law enforcement
- 35 agency, shall not remove or initiate proceedings to

-9-

- 1 remove a patient under the age of eighteen from the
- 2 home of a parent based solely upon the parent's or
- 3 patient's possession or use of medical cannabidiol or
- 4 medical cannabidiol products as authorized under this
- 5 chapter.
- 6 4. The department, the department of
- 7 transportation, and any health care practitioner,
- 8 including any authorized agent or employee thereof, are
- 9 not subject to any civil or disciplinary penalties by
- 10 the board of medicine or any business, occupational,
- ll or professional licensing board or entity, solely for
- 12 activities conducted relating to a patient's possession
- 13 or use of medical cannabidiol or medical cannabidiol
- 14 products as authorized under this chapter. Nothing in
- 15 this section affects a professional licensing board
- 16 from taking action in response to violations of any
- 17 other section of law.
- 18 5. Notwithstanding any law to the contrary, the
- 19 department, the department of transportation, the
- 20 governor, or any employee of any state agency shall not
- 21 be held civilly or criminally liable for any injury,
- 22 loss of property, personal injury, or death caused by
- 23 any act or omission while acting within the scope of
- 24 office or employment as authorized under this chapter.
- 25 6. An attorney shall not be subject to disciplinary
- 26 action by the Iowa supreme court or attorney
- 27 disciplinary board for providing legal assistance to
- 28 a patient, primary caregiver, or others based upon a
- 29 patient's or primary caregiver's possession or use of
- 30 medical cannabidiol as authorized under this chapter.
- 31 7. Possession of a medical cannabidiol registration
- 32 card or an application for a medical cannabidiol
- 33 registration card by a person entitled to possess or
- 34 apply for a medical cannabidiol registration card shall
- 35 not constitute probable cause or reasonable suspicion,

- 1 and shall not be used to support a search of the person
- 2 or property of the person possessing or applying for
- 3 the medical cannabidiol registration card, or otherwise
- 4 subject the person or property of the person to
- 5 inspection by any governmental agency.
- 6 Sec. 8. <u>NEW SECTION</u>. **124E.7 Medical cannabidiol** 7 source.
- 8 Medical cannabidiol provided exclusively pursuant to
- 9 a written certification of a health care practitioner
- 10 shall be obtained from an out-of-state source.
- 11 Sec. 9. NEW SECTION. 124E.8 Penalties.
- 12 A person who knowingly or intentionally possesses
- 13 or uses medical cannabidiol in violation of the
- 14 requirements of this chapter is subject to the
- 15 penalties provided under chapters 124 and 453B.
- 16 Sec. 10. NEW SECTION. 124E.9 Use of medical
- 17 cannabidiol smoking prohibited.
- 18 A patient shall not consume medical cannabidiol
- 19 possessed or used as authorized under this chapter by
- 20 smoking medical cannabidiol.
- 21 Sec. 11. NEW SECTION. 124E.10 Medical cannabidiol
- 22 therapeutic research impact assessment task force.
- 23 1. A medical cannabidiol therapeutic research
- 24 impact assessment task force is created within the
- 25 department. The task force shall consist of the
- 26 following members:
- 27 a. Four members of the general assembly who shall
- 28 serve as ex officio, nonvoting members to be appointed
- 29 as follows:
- 30 (1) Two members of the house of representatives,
- 31 one selected by the speaker of the house of
- 32 representatives, the other selected by the minority
- 33 leader of the house of representatives.
- 34 (2) Two members of the senate, one selected by the
- 35 majority leader of the senate, the other selected by

- 1 the minority leader of the senate.
- Eighteen voting members as follows: 2
- (1) Two members who are primary caregivers who are
- 4 patients with a valid medical cannabidiol registration
- 5 card.
- Two members who are primary caregivers who are
- 7 parents of patients under age eighteen.
- (3) Four members representing health care
- 9 providers, including one licensed pharmacist.
- 10 (4) Four members representing law enforcement, one
- 11 from the Iowa police chiefs association, one from the
- 12 Iowa state sheriffs' and deputies' association, one
- 13 from the Iowa peace officers association, and one from
- 14 the Iowa county attorneys association.
- (5) Four members representing substance use 15
- 16 disorder treatment providers.
- (6) One member representing the department of 17
- 18 public health.
- 19 (7) One member representing the department of
- 20 public safety.
- 21 Task force members shall be appointed by July 2.
- 22 15, 2016, and shall meet annually.
- Two co-chairpersons of the task force shall be 23
- 24 chosen from the members. One co-chairperson shall be
- 25 selected by the speaker of the house of representatives
- 26 and the other co-chairperson shall be selected by the
- 27 majority leader of the senate.
- The task force shall review and evaluate the 28
- 29 impact of the use of medical cannabidiol, including
- 30 Iowa's experience and the experience of other states
- 31 involving medical cannabidiol, on all of the following:
- 32 Program design and implementation.
- 33 b. The impact on the health care provider
- 34 community.
- 35 c. Patient experiences.

- 1 d. The impact on the incidence of substance abuse.
- 2 e. Access to and quality of medical cannabidiol and
- 3 medical cannabidiol products.
- 4 f. The impact on law enforcement and prosecutions.
- 5 g. Public awareness and perception.
- 6 h. Any unintended consequences.
- 7 5. The task force shall submit its recommendations
- 8 to the governor and the general assembly no later than
- 9 December 15 in each year the task force is required to 10 meet.
- 11 6. This section is repealed July 1, 2021.
- 12 Sec. 12. Section 730.5, subsection 11, Code 2016,
- 13 is amended by adding the following new paragraph:
- 14 NEW PARAGRAPH. f. Testing or taking action against
- 15 an individual with a confirmed positive test result due
- 16 to the individual's use of cannabidiol as authorized
- 17 under chapter 124E.
- 18 Sec. 13. TRANSITION PROVISIONS. A medical
- 19 cannabidiol registration card issued under chapter
- 20 124D prior to the effective date of this division of
- 21 this Act, remains effective and continues in effect
- 22 as issued for the twelve-month period following its
- 23 issuance. This division of this Act does not preclude
- 24 the medical cannabidiol cardholder from seeking to
- 25 renew the holder's medical cannabidiol registration
- 26 card under this division of this Act prior to the
- 27 expiration of the twelve-month period.
- 28 Sec. 14. REPEAL. Chapter 124D, Code 2016, is
- 29 repealed.
- 30 Sec. 15. EFFECTIVE UPON ENACTMENT. This division
- 31 of this Act, being deemed of immediate importance,
- 32 takes effect upon enactment.
- 33 DIVISION II
- 34 SYNTHETIC DRUGS
- 35 Sec. 16. Section 124.101, Code 2016, is amended by

- 1 adding the following new subsection:
- 2 NEW SUBSECTION. 15A. "Imitation controlled
- 3 substance" means a substance which is not a controlled
- 4 substance but which by color, shape, size, markings,
- 5 and other aspects of dosage unit appearance, and
- 6 packaging or other factors, appears to be or resembles
- 7 a controlled substance. The board of pharmacy may
- 8 designate a substance as an imitation controlled
- 9 substance pursuant to the board's rulemaking authority
- 10 and in accordance with chapter 17A. "Imitation
- 11 controlled substance" also means any substance
- 12 determined to be an imitation controlled substance
- 13 pursuant to section 124.101B.
- 14 Sec. 17. NEW SECTION. 124.101B Factors indicating
- 15 an imitation controlled substance.
- 16 If a substance has not been designated as an
- 17 imitation controlled substance by the board of pharmacy
- 18 and if dosage unit appearance alone does not establish
- 19 that a substance is an imitation controlled substance,
- 20 the following factors may be considered in determining
- 21 whether the substance is an imitation controlled
- 22 substance:
- 23 1. The person in control of the substance expressly
- 24 or impliedly represents that the substance has the
- 25 effect of a controlled substance.
- 26 2. The person in control of the substance expressly
- 27 or impliedly represents that the substance because
- 28 of its nature or appearance can be sold or delivered
- 29 as a controlled substance or as a substitute for a
- 30 controlled substance.
- 31 3. The person in control of the substance either
- 32 demands or receives money or other property having a
- 33 value substantially greater than the actual value of
- 34 the substance as consideration for delivery of the
- 35 substance.

```
Sec. 18. Section 124.201, subsection 4, Code 2016,
 1
 2 is amended to read as follows:
          If any new substance is designated as a
 4 controlled substance under federal law and notice of
 5 the designation is given to the board, the board shall
 6 similarly designate as controlled the new substance
 7 under this chapter after the expiration of thirty days
 8 from publication in the federal register of a final
 9 order designating a new substance as a controlled
10 substance, unless within that thirty-day period the
11 board objects to the new designation. In that case
12 the board shall publish the reasons for objection and
13 afford all interested parties an opportunity to be
14 heard. At the conclusion of the hearing the board
15 shall announce its decision. Upon publication of
16 objection to a new substance being designated as a
17 controlled substance under this chapter by the board,
18 control under this chapter is stayed until the board
19 publishes its decision. If a substance is designated
20 as controlled by the board under this subsection the
21 control shall be considered a temporary and if, within
22 sixty days after the next regular session of the
23 general assembly convenes, the general assembly has not
24 made the corresponding changes in this chapter, the
25 temporary designation of control of the substance by
26 the board shall be nullified amendment to the schedules
27 of controlled substances in this chapter.
28 board so designates a substance as controlled, which
29 is considered a temporary amendment to the schedules
30 of controlled substances in this chapter, and if
31 the general assembly does not amend this chapter to
32 enact the temporary amendment and make the enactment
33 effective within two years from the date the temporary
34 amendment first became effective, the temporary
```

35 amendment is repealed by operation of law two years

- 1 from the effective date of the temporary amendment. A
- 2 temporary amendment repealed by operation of law is
- 3 subject to section 4.13 relating to the construction
- 4 of statutes and the application of a general savings
- 5 provision.
- 6 Sec. 19. Section 124.204, subsection 4, paragraph
- 7 ai, subparagraphs (3), (4), and (5), Code 2016, are
- 8 amended by striking the subparagraphs.
- 9 Sec. 20. Section 124.204, subsection 4, paragraph
- 10 aj, Code 2016, is amended by striking the paragraph and
- ll inserting in lieu thereof the following:
- 12 aj. 5-methoxy-N, N-dimethyltryptamine.
- 13 Some trade or other names:
- 14 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT.
- 15 Sec. 21. Section 124.204, subsection 4, paragraph
- 16 ak, Code 2016, is amended by striking the paragraph and
- 17 inserting in lieu thereof the following:
- 18 ak. 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine
- 19 (2C-E).
- 20 Sec. 22. Section 124.204, subsection 4, Code 2016,
- 21 is amended by adding the following new paragraphs:
- 22 NEW PARAGRAPH. al. 2-(2,5-Dimethoxy-4-
- 23 methylphenyl)ethanamine (2C-D).
- NEW PARAGRAPH. am. 2-(4-Chloro-2,5-
- 25 dimethoxyphenyl)ethanamine (2C-C).
- 26 NEW PARAGRAPH. an. 2-(4-Iodo-2,5-
- 27 dimethoxyphenyl)ethanamine (2C-I).
- 28 NEW PARAGRAPH. *ao.* 2-[4-(Ethylthio)-2,5-
- 29 dimethoxyphenyl]ethanamine (2C-T-2).
- NEW PARAGRAPH. ap. 2-[4-(Isopropylthio)-2,5-
- 31 dimethoxyphenyl]ethanamine (2C-T-4).
- 32 NEW PARAGRAPH. aq. 2-(2,5-Dimethoxyphenyl)
- 33 ethanamine (2C-H).
- NEW PARAGRAPH. ar. 2-(2,5-Dimethoxy-4-
- 35 nitrophenyl)ethanamine (2C-N).

- 1 NEW PARAGRAPH. as. 2-(2,5-Dimethoxy-4-(n)-
- 2 propylphenyl)ethanamine (2C-P).
- 3 Sec. 23. Section 124.204, subsection 6, paragraph
- 4 i, subparagraph (3), Code 2016, is amended by striking
- 5 the subparagraph and inserting in lieu thereof the
- 6 following:
- 7 (3) 3,4-Methylenedioxy-N-methylcathinone
- 8 (methylone).
- 9 Sec. 24. Section 124.204, subsection 6, paragraph
- 10 i, subparagraphs (23), (24), (25), and (26), Code 2016,
- 11 are amended by striking the subparagraphs.
- 12 Sec. 25. Section 124.204, subsection 9, Code 2016,
- 13 is amended by adding the following new paragraphs:
- 14 NEW PARAGRAPH. Oa. HU-210.
- 15 [(6aR,10aR)-9-(hydroxymethyl)-
- 16 6,6-dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a-
- 17 tetrahydrobenzo[c] chromen-1-ol)].
- NEW PARAGRAPH. 00a. HU-211(dexanabinol,
- 19 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
- 20 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]
- 21 chromen-1-ol).
- 22 NEW PARAGRAPH. 000a. Unless specifically exempted
- 23 or unless listed in another schedule, any material,
- 24 compound, mixture, or preparation which contains any
- 25 quantity of cannabimimetic agents, or which contains
- 26 their salts, isomers, and salts of isomers whenever the
- 27 existence of such salts, isomers, and salts of isomers
- 28 is possible within the specific chemical designation.
- 29 (1) The term "cannabimimetic agents" means any
- 30 substance that is a cannabinoid receptor type 1 (CB1
- 31 receptor) agonist as demonstrated by binding studies
- 32 and functional assays within any of the following
- 33 structural classes:
- 34 (a) 2-(3-hydroxycyclohexyl)phenol with substitution
- 35 at the 5-position of the phenolic ring by alkyl or

- 1 alkenyl, whether or not substituted on the cyclohexyl
- 2 ring to any extent.
- (b) 3-(1-naphthoy1)indole or
- 4 3-(1-naphthylmethane)indole by substitution at the
- 5 nitrogen atom of the indole ring, whether or not
- 6 further substituted on the indole ring to any extent,
- 7 whether or not substituted on the naphthoyl or naphthyl
- 8 ring to any extent.
- 3-(1-naphthoy1)pyrrole by substitution at the (C)
- 10 nitrogen atom of the pyrrole ring, whether or not
- 11 further substituted in the pyrrole ring to any extent,
- 12 whether or not substituted on the naphthoyl ring to any
- 13 extent.
- (d) 14 1-(1-naphthylmethylene)indene by substitution
- 15 of the 3-position of the indene ring, whether or not
- 16 further substituted in the indene ring to any extent,
- 17 whether or not substituted on the naphthyl ring to any
- 18 extent.
- 19 3-phenylacetylindole or 3-benzoylindole by
- 20 substitution at the nitrogen atom of the indole ring,
- 21 whether or not further substituted in the indole ring
- 22 to any extent, whether or not substituted on the phenyl
- 23 ring to any extent.
- 24 (2) Such terms include:
- 25 (a) CP 47,497 and homologues
- 26 5-(1,1-dimethylheptyl)-2-
- 27 [(lR,3S)-3-hydroxycyclohexl]phenol.
- 28 (b) JWH-018 and AM678
- 29 1-Pentyl-3-(1-naphthoyl)indole.
- 30 (c) JWH-073 1-Butyl-3-(1-naphthoyl)indole.
- 31 (d) JWH-200[1-[2-(4-morpholinyl)ethyl]-1H-
- 32 indol-3-yl]-1-naphthalenyl-methanone.
- 33 JWH-19 1-hexyl-3-(1-naphthoy1)indole. (e)
- 34 (f) JWH-81
- 35 l-pentyl-3-[1-(4-methoxynaphthoyl)]indole.

rh/rj

```
1 (g) JWH-122
```

- 2 1-pentyl-3-(4-methyl-1-naphthoyl)indole.
- 3 (h) JWH-250
- 4 1-pentyl-3-(2-methoxyphenylacetyl)indole.
- 5 (i) RCS-4 and SR-19
- 6 l-pentyl-3-[(4methoxy)-benzoyl]indole.
- 7 (j) RCS-8 and SR 18 1-cyclohexylethyl-3-
- 8 (2-methoxyphenylacetyl)indole.
- 9 (k) AM2201
- 10 1-(5-fluoropentyl)-3-(1-naphthoyl)indole.
- 11 (1) JWH-203
- 12 1-pentyl-3-(2-chlorophenylacetyl)indole.
- 13 (m) JWH-398
- 14 1-pentyl-3-(4-chloro-1-naphthoyl)indole.
- 15 (n) AM694
- 16 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.
- 17 (o) Cannabicyclohexanol or CP-47,497 C8-homolog 5-
- 18 (1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol.
- 19 Sec. 26. Section 124.208, subsection 5, paragraph
- 20 a, subparagraphs (3) and (4), Code 2016, are amended by
- 21 striking the subparagraphs.
- 22 Sec. 27. Section 124.210, subsection 2, Code 2016,
- 23 is amended by adding the following new paragraph:
- NEW PARAGRAPH. c. 2-[(dimethylamino)methyl]-1-
- 25 (3-methoxyphenyl)cyclohexanol, its salts, optical
- 26 and geometric isomers, and salts of these isomers
- 27 (including tramadol).
- 28 Sec. 28. Section 124.210, subsection 3, Code 2016,
- 29 is amended by adding the following new paragraphs:
- 30 NEW PARAGRAPH. bb. Alfaxalone.
- 31 NEW PARAGRAPH. bc. Suvorexant.
- 32 Sec. 29. Section 124.401, subsection 1, unnumbered
- 33 paragraph 1, Code 2016, is amended to read as follows:
- 34 Except as authorized by this chapter, it is unlawful
- 35 for any person to manufacture, deliver, or possess with

- 1 the intent to manufacture or deliver, a controlled
- 2 substance, a counterfeit substance, or a simulated
- 3 controlled substance, or an imitation controlled
- 4 substance, or to act with, enter into a common scheme
- 5 or design with, or conspire with one or more other
- 6 persons to manufacture, deliver, or possess with
- 7 the intent to manufacture or deliver a controlled
- 8 substance, a counterfeit substance, or a simulated
- 9 controlled substance, or an imitation controlled
- 10 substance.
- 11 Sec. 30. Section 124.401, subsection 1, paragraph
- 12 a, unnumbered paragraph 1, Code 2016, is amended to
- 13 read as follows:
- 14 Violation of this subsection, with respect to
- 15 the following controlled substances, counterfeit
- 16 substances, or simulated controlled substances, or
- 17 imitation controlled substances, is a class "B" felony,
- 18 and notwithstanding section 902.9, subsection 1,
- 19 paragraph "b", shall be punished by confinement for no
- 20 more than fifty years and a fine of not more than one
- 21 million dollars:
- 22 Sec. 31. Section 124.401, subsection 1, paragraph
- 23 a, Code 2016, is amended by adding the following new
- 24 subparagraph:
- 25 NEW SUBPARAGRAPH. (8) More than ten kilograms of a
- 26 mixture or substance containing any detectable amount
- 27 of those substances identified in section 124.204,
- 28 subsection 9.
- 29 Sec. 32. Section 124.401, subsection 1, paragraph
- 30 b, unnumbered paragraph 1, Code 2016, is amended to
- 31 read as follows:
- 32 Violation of this subsection with respect to
- 33 the following controlled substances, counterfeit
- 34 substances, or simulated controlled substances, or
- 35 imitation controlled substances is a class "B" felony,

- 1 and in addition to the provisions of section 902.9,
- 2 subsection 1, paragraph "b", shall be punished by a
- 3 fine of not less than five thousand dollars nor more
- 4 than one hundred thousand dollars:
- 5 Sec. 33. Section 124.401, subsection 1, paragraph
- 6 b, Code 2016, is amended by adding the following new
- 7 subparagraph:
- 8 NEW SUBPARAGRAPH. (9) More than five kilograms but
- 9 not more than ten kilograms of a mixture or substance
- 10 containing any detectable amount of those substances
- 11 identified in section 124.204, subsection 9.
- 12 Sec. 34. Section 124.401, subsection 1, paragraph
- 13 c, unnumbered paragraph 1, Code 2016, is amended to
- 14 read as follows:
- 15 Violation of this subsection with respect to
- 16 the following controlled substances, counterfeit
- 17 substances, or simulated controlled substances, or
- 18 imitation controlled substances is a class "C" felony,
- 19 and in addition to the provisions of section 902.9,
- 20 subsection 1, paragraph "d", shall be punished by a
- 21 fine of not less than one thousand dollars nor more
- 22 than fifty thousand dollars:
- Sec. 35. Section 124.401, subsection 1, paragraph
- 24 c, Code 2016, is amended by adding the following new
- 25 subparagraph:
- 26 NEW SUBPARAGRAPH. (7A) Five kilograms or less of a
- 27 mixture or substance containing any detectable amount
- 28 of those substances identified in section 124.204,
- 29 subsection 9.
- 30 Sec. 36. Section 124.401, subsection 1, paragraph
- 31 c, subparagraph (8), Code 2016, is amended to read as
- 32 follows:
- 33 (8) Any other controlled substance, counterfeit
- 34 substance, or simulated controlled substance, or
- 35 imitation controlled substance classified in schedule

- 1 I, II, or III, except as provided in paragraph "d".
- Sec. 37. Section 124.401, subsection 1, paragraph 2
- 3 d, Code 2016, is amended to read as follows:
- d. Violation of this subsection, with respect
- 5 to any other controlled substances, counterfeit
- 6 substances, or simulated controlled substances
- 7 classified in section 124.204, subsection 4, paragraph
- 8 "ai", or section 124.204, subsection 6, paragraph "i",
- 9 or, or imitation controlled substances classified
- 10 in schedule IV or V is an aggravated misdemeanor.
- 11 However, violation of this subsection involving
- 12 fifty kilograms or less of marijuana or involving
- 13 flunitrazepam is a class "D" felony.
- Sec. 38. Section 124.401, subsection 2, Code 2016, 14
- 15 is amended to read as follows:
- 16 2. If the same person commits two or more acts
- 17 which are in violation of subsection 1 and the acts
- 18 occur in approximately the same location or time
- 19 period so that the acts can be attributed to a single
- 20 scheme, plan, or conspiracy, the acts may be considered
- 21 a single violation and the weight of the controlled
- 22 substances, counterfeit substances, or simulated
- 23 controlled substances, or imitation controlled
- 24 substances involved may be combined for purposes of
- 25 charging the offender.
- Sec. 39. Section 124.401, subsection 5, unnumbered 26
- 27 paragraph 1, Code 2016, is amended to read as follows:
- It is unlawful for any person knowingly or 28
- 29 intentionally to possess a controlled substance unless
- 30 such substance was obtained directly from, or pursuant
- 31 to, a valid prescription or order of a practitioner
- 32 while acting in the course of the practitioner's
- 33 professional practice, or except as otherwise
- 34 authorized by this chapter. Any person who violates
- 35 this subsection is guilty of a serious misdemeanor for

- l a first offense. A person who commits a violation of
- 2 this subsection and who has previously been convicted
- 3 of violating this chapter or chapter 124A, 124B, or
- 4 453B, or chapter 124A as it existed prior to July
- 5 1, 2016, is guilty of an aggravated misdemeanor. A
- 6 person who commits a violation of this subsection and
- 7 has previously been convicted two or more times of
- 8 violating this chapter or chapter 124A, 124B, or 453B,
- 9 or chapter 124A as it existed prior to July 1, 2016, is
- 10 quilty of a class "D" felony.
- Sec. 40. Section 124.401A, Code 2016, is amended to 11
- 12 read as follows:
- 13 124.401A Enhanced penalty for manufacture or
- 14 distribution to persons on certain real property.
- In addition to any other penalties provided in
- 16 this chapter, a person who is eighteen years of age
- 17 or older who unlawfully manufactures with intent to
- 18 distribute, distributes, or possesses with intent to
- 19 distribute a substance or counterfeit substance listed
- 20 in schedule I, II, or III, or a simulated or imitation
- 21 controlled substance represented to be a controlled
- 22 substance classified in schedule I, II, or III, to
- 23 another person who is eighteen years of age or older in
- 24 or on, or within one thousand feet of the real property
- 25 comprising a public or private elementary or secondary
- 26 school, public park, public swimming pool, public
- 27 recreation center, or on a marked school bus, may be
- 28 sentenced up to an additional term of confinement of
- 29 five years.
- 30 Section 124.401B, Code 2016, is amended to Sec. 41.
- 31 read as follows:
- 32 124.401B Possession of controlled substances on
- 33 certain real property additional penalty.
- 34 In addition to any other penalties provided in this
- 35 chapter or another chapter, a person who unlawfully

- 1 possesses a substance listed in schedule I, II, or
- 2 III, or a simulated or imitation controlled substance
- 3 represented to be a controlled substance classified
- 4 in schedule I, II, or III, in or on, or within one
- 5 thousand feet of the real property comprising a public
- 6 or private elementary or secondary school, public park,
- 7 public swimming pool, public recreation center, or on
- 8 a marked school bus, may be sentenced to one hundred
- 9 hours of community service work for a public agency
- 10 or a nonprofit charitable organization. The court
- 11 shall provide the offender with a written statement of
- 12 the terms and monitoring provisions of the community
- 13 service.
- 14 Sec. 42. Section 124.406, subsection 2, Code 2016,
- 15 is amended to read as follows:
- 16 2. A person who is eighteen years of age or older
- 17 who:
- 18 a. Unlawfully distributes or possesses with the
- 19 intent to distribute a counterfeit substance listed
- 20 in schedule I or II, or a simulated or imitation
- 21 controlled substance represented to be a substance
- 22 classified in schedule I or II, to a person under
- 23 eighteen years of age commits a class "B" felony.
- 24 However, if the substance was distributed in or on,
- 25 or within one thousand feet of, the real property
- 26 comprising a public or private elementary or secondary
- 27 school, public park, public swimming pool, public
- 28 recreation center, or on a marked school bus, the
- 29 person shall serve a minimum term of confinement of ten
- 30 years.
- 31 b. Unlawfully distributes or possesses with intent
- 32 to distribute a counterfeit substance listed in
- 33 schedule III, or a simulated or imitation controlled
- 34 substance represented to be any substance listed in
- 35 schedule III, to a person under eighteen years of age

- 1 who is at least three years younger than the violator
- 2 commits a class "C" felony.
- c. Unlawfully distributes a counterfeit substance
- 4 listed in schedule IV or V, or a simulated or imitation
- 5 controlled substance represented to be a substance
- 6 listed in schedule IV or V, to a person under eighteen
- 7 years of age who is at least three years younger than
- 8 the violator commits an aggravated misdemeanor.
- Sec. 43. Section 124.415, Code 2016, is amended to
- 10 read as follows:
- 124.415 Parental and school notification persons 11
- 12 under eighteen years of age.
- 13 A peace officer shall make a reasonable effort to
- 14 identify a person under the age of eighteen discovered
- 15 to be in possession of a controlled substance,
- 16 counterfeit substance, or simulated controlled
- 17 substance, or imitation controlled substance in
- 18 violation of this chapter, and if the person is not
- 19 referred to juvenile court, the law enforcement agency
- 20 of which the peace officer is an employee shall make
- 21 a reasonable attempt to notify the person's custodial
- 22 parent or legal guardian of such possession, whether
- 23 or not the person is arrested, unless the officer has
- 24 reasonable grounds to believe that such notification
- 25 is not in the best interests of the person or will
- 26 endanger that person. If the person is taken into
- 27 custody, the peace officer shall notify a juvenile
- 28 court officer who shall make a reasonable effort to
- 29 identify the elementary or secondary school the person
- 30 attends, if any, and to notify the superintendent of
- 31 the school district, the superintendent's designee,
- 32 or the authorities in charge of the nonpublic school
- 33 of the taking into custody. A reasonable attempt to
- 34 notify the person includes but is not limited to a
- 35 telephone call or notice by first-class mail.

- Sec. 44. NEW SECTION. 124.417 Imitation controlled 1
- 2 substances exceptions.
- It is not unlawful under this chapter for a person
- 4 registered under section 124.302, to manufacture,
- 5 deliver, or possess with the intent to manufacture or
- 6 deliver, or to act with, one or more other persons
- 7 to manufacture, deliver, or possess with the intent
- 8 to manufacture or deliver an imitation controlled
- 9 substance for use as a placebo by a registered
- 10 practitioner in the course of professional practice or
- ll research.
- 12 Section 124.502, subsection 1, paragraph Sec. 45.
- 13 a, Code 2016, is amended to read as follows:
- a. A district judge or district associate judge,
- 15 within the court's jurisdiction, and upon proper
- 16 oath or affirmation showing probable cause, may issue
- 17 warrants for the purpose of conducting administrative
- 18 inspections under this chapter or a related rule
- 19 or under chapter 124A. The warrant may also permit
- 20 seizures of property appropriate to the inspections.
- 21 For purposes of the issuance of administrative
- 22 inspection warrants, probable cause exists upon showing
- 23 a valid public interest in the effective enforcement
- 24 of the statute or related rules, sufficient to justify
- 25 administrative inspection of the area, premises,
- 26 building, or conveyance in the circumstances specified
- 27 in the application for the warrant.
- 28 Sec. 46. Section 155A.6, subsection 3, Code 2016,
- 29 is amended to read as follows:
- The board shall establish standards for 30
- 31 pharmacist-intern registration and may deny, suspend,
- 32 or revoke a pharmacist-intern registration for failure
- 33 to meet the standards or for any violation of the laws
- 34 of this state, another state, or the United States
- 35 relating to prescription drugs, controlled substances,

- 1 or nonprescription drugs, or for any violation of this
- 2 chapter or chapter 124, 124A, 124B, 126, 147, or 205,
- 3 or any rule of the board.
- 4 Sec. 47. Section 155A.6A, subsection 5, Code 2016,
- 5 is amended to read as follows:
- The board may deny, suspend, or revoke the
- 7 registration of, or otherwise discipline, a registered
- 8 pharmacy technician for any violation of the laws
- 9 of this state, another state, or the United States
- 10 relating to prescription drugs, controlled substances,
- ll or nonprescription drugs, or for any violation of this
- 12 chapter or chapter 124, 124A, 124B, 126, 147, 205, or
- 13 272C, or any rule of the board.
- 14 Sec. 48. Section 155A.6B, subsection 5, Code 2016,
- 15 is amended to read as follows:
- 16 5. The board may deny, suspend, or revoke the
- 17 registration of a pharmacy support person or otherwise
- 18 discipline the pharmacy support person for any
- 19 violation of the laws of this state, another state,
- 20 or the United States relating to prescription drugs,
- 21 controlled substances, or nonprescription drugs, or for
- 22 any violation of this chapter or chapter 124, 124A,
- 23 124B, 126, 147, 205, or 272C, or any rule of the board.
- 24 Sec. 49. Section 155A.13A, subsection 3, Code 2016,
- 25 is amended to read as follows:
- 3. Discipline. The board may deny, suspend, or
- 27 revoke a nonresident pharmacy license for any violation
- 28 of this section, section 155A.15, subsection 2,
- 29 paragraph "a", "b", "d", "e", "f", "g", "h", or "i",
- 30 chapter 124,  $\frac{124A_{7}}{124B_{7}}$  124B, 126, or 205, or a rule of the
- 31 board.
- 32 Sec. 50. Section 155A.17, subsection 2, Code 2016,
- 33 is amended to read as follows:
- 34 2. The board shall establish standards for drug
- 35 wholesaler licensure and may define specific types of

- 1 wholesaler licenses. The board may deny, suspend, or
- 2 revoke a drug wholesale license for failure to meet the
- 3 applicable standards or for a violation of the laws
- 4 of this state, another state, or the United States
- 5 relating to prescription drugs, devices, or controlled
- 6 substances, or for a violation of this chapter, chapter
- 7 124, 124A, 124B, 126, or 205, or a rule of the board.
- 8 Sec. 51. Section 155A.42, subsection 4, Code 2016,
- 9 is amended to read as follows:
- 10 4. The board may deny, suspend, or revoke a limited
- 11 drug and device distributor's license for failure to
- 12 meet the applicable standards or for a violation of
- 13 the laws of this state, another state, or the United
- 14 States relating to prescription drugs or controlled
- 15 substances, or for a violation of this chapter, chapter
- 16 124, <del>124A,</del> 124B, 126, 205, or 272C, or a rule of the
- 17 board.
- 18 Sec. 52. REPEAL. Chapter 124A, Code 2016, is
- 19 repealed.>
- 20 2. Title page, by striking lines 1 through 5 and
- 21 inserting <An Act relating to controlled substances
- 22 and the medical cannabidiol Act, including imitation
- 23 controlled substances, temporarily designating
- 24 substances as controlled substances, including
- 25 effective date provisions, and providing criminal
- 26 penalties.>>>

NUNN of Polk

rh/rj